

BIOTIME INC  
Form 8-K  
December 30, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): December 30, 2004.

**BioTime, Inc.**

(Exact name of registrant as specified in its charter)

**California**  
(State or other jurisdiction  
of incorporation)

**1-12830**  
(Commission File Number)

**94-3127919**  
(IRS Employer  
Identification No.)

**935 Pardee Street**  
**Berkeley, California 94710**  
(Address of principal executive offices)

**(510) 845-9535**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01- Other Events

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

Press Release Dated December 30, 2004

---

**Table of Contents**

*Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as Aexpects, @ Amay, @ Awill, @ Aanticipates, @ & #065;intends, @ Aplans, @ Abelieves, @ Aseeks, @ & #065;estimates, @ and similar expressions identify forward-looking statements.*

**Section 8- Other Events**

**Item 8.01- Other Events**

On December 30, 2004, BioTime, Inc. issued a press release announcing that it has entered into an agreement with Summit Pharmaceuticals International Corporation, an affiliate of Sumitomo Corporation, to develop Hextend and PentaLyte for the Japanese market. A copy of the press release is attached as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.

**Section 9-Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits.**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release dated December 30, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 30, 2004

**BIOTIME, INC.**

By /s/ Steven Seiberger

---

Steven Seiberger,  
Chief Financial Officer

**Table of Contents**

**Exhibit  
Numbers**

**Description**

99.1	Press Release dated December 30, 2004
------	---------------------------------------

3